enGene Therapeutics Inc.: Form 10-Q for the period ended Jan 31, 2024
Filed with the SEC on Mar 11, 2024 and accepted by EDGAR at Mar 11, 2024, 17:12 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-11-01 to 2024-01-31 | $5.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-11-01 to 2024-01-31 | −$10.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-11-01 to 2024-01-31 | $563.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-11-01 to 2024-01-31 | −$30.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-11-01 to 2024-01-31 | −$10.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-11-01 to 2024-01-31 | $0.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-11-01 to 2024-01-31 | $0.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-11-01 to 2024-01-31 | 23,197,976 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-11-01 to 2024-01-31 | −$7.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-11-01 to 2024-01-31 | $506.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-01-31 | $85.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-01-31 | $89.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-01-31 | $93.4m | us-gaap:Assets |
| Current liabilities | At period end2024-01-31 | $6.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-01-31 | $31.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-01-31 | $62.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-029413. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.